Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26334857 | 0.91 | CYP2D6 (0.39) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL26334849 | 0.89 | CYP2D6 (0.42) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL26334850 | 0.89 | CYP2D6 (0.42) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL26334858 | 0.89 | CYP2D6 (0.42) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL16417850 | 0.88 | LPAR3 (0.47) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL26460406 | 0.87 | LPAR3 (0.36) | LPAR3LPAR2LPAR1TSHRCYP2D6 | |
| SCHEMBL12914743 | 0.84 | LPAR3 (0.52) | LPAR3LPAR2LPAR1TSHRPPARD | |
| SCHEMBL17327639 | 0.84 | LPAR3 (0.37) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL25584062 | 0.82 | LPAR3 (0.40) | LPAR3LPAR2LPAR1CYP2D6CYP1A2 | |
| SCHEMBL11994572 | 0.80 | LMNA (0.46) | LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008613-B2 | Tagged nucleotides useful for nanopore detection | Roche Sequencing Solutions, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200216894-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | Roche Sequencing Solutions, Inc. (US) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216894-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | PHAX, POLRMT, POLN | LPAR3 3474/4885LPAR2 3499/4885LPAR1 3376/4885 |
| US-11008613-B2 | Tagged nucleotides useful for nanopore detection | PHAX, POLRMT, POLN | LPAR3 3474/4885LPAR2 3499/4885LPAR1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.